Rapid implementation of a new ambulatory infusion location for patients with COVID-19 to receive monoclonal antibody therapy

Am J Health Syst Pharm. 2021 Jun 23;78(13):1166-1168. doi: 10.1093/ajhp/zxab054.

Abstract

In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Keywords: COVID-19; asirivimab/indevimab; bamlanivimab; casirivimab/indevimab; infusion; monoclonal antibody.

MeSH terms

  • Ambulatory Care Facilities / supply & distribution*
  • Antibodies, Monoclonal / administration & dosage*
  • COVID-19 Drug Treatment*
  • Community Pharmacy Services
  • Humans
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal